Author Correction: Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage ◽

Assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer

Annals of Oncology ◽

10.1093/annonc/mdz155.199 ◽

2019 ◽

Vol 30 ◽

pp. iv54

Author(s):

A. Kr ◽

S.S. P ◽

R. Kumar C

Keyword(s):

Colorectal Cancer ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage ◽

Exploratory analyses assessing the impact of early tumour shrinkage and depth of response on survival outcomes in patients with RAS wild-type metastatic colorectal cancer receiving treatment in three randomised panitumumab trials

Journal of Cancer Research and Clinical Oncology ◽

10.1007/s00432-017-2534-z ◽

2017 ◽

Vol 144 (2) ◽

pp. 321-335 ◽

Cited By ~ 12

Author(s):

Julien Taieb ◽

Fernando Rivera ◽

Salvatore Siena ◽

Meinolf Karthaus ◽

Manuel Valladares-Ayerbes ◽

...

Keyword(s):

Colorectal Cancer ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage ◽

P-78 Early tumour shrinkage, depth of response and survival outcomes for RAS wild-type metastatic colorectal cancer patients classified by baseline tumour load: Retrospective pooled analysis of panitumumab PRIME/PEAK studies

Annals of Oncology ◽

10.1016/j.annonc.2020.04.160 ◽

2020 ◽

Vol 31 ◽

pp. S114-S115

Author(s):

F. Loupakis ◽

M. Peeters ◽

M. Geissler ◽

D. Modest ◽

M. Valladares-Ayerbes ◽

...

Keyword(s):

Colorectal Cancer ◽

Cancer Patients ◽

Pooled Analysis ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Load ◽

Tumour Shrinkage ◽

Colorectal Cancer Patients

Early tumour shrinkage (ETS), depth of response (DpR) and associated survival outcomes in patients (pts) with RAS wild type (WT) metastatic colorectal cancer (mCRC) classified according to Köhne prognostic category: Retrospective analysis of the panitumumab (Pmab) PRIME study

Annals of Oncology ◽

10.1093/annonc/mdz246.049 ◽

2019 ◽

Vol 30 ◽

pp. v216

Author(s):

A. Sartore-Bianchi ◽

M. Peeters ◽

M. Geissler ◽

J. Taieb ◽

P. García-Alfonso ◽

...

Keyword(s):

Colorectal Cancer ◽

Retrospective Analysis ◽

Survival Outcomes ◽

Wild Type ◽

Depth Of Response ◽

Tumour Shrinkage

O-015 Association between depth of response (DpR) and survival outcomes in RAS-wild-type (wt) patients with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI plus cetuximab once-every-2-weeks in the APEC study

Annals of Oncology ◽

10.1093/annonc/mdw198.15 ◽

2016 ◽

Vol 27 ◽

pp. ii123

Author(s):

A.-L. Cheng ◽

G. Cornelio ◽

L. Shen ◽

T. Price ◽

T.-S. Yang ◽

...

Keyword(s):

Colorectal Cancer ◽

Survival Outcomes ◽

Wild Type ◽

First Line ◽

Depth Of Response

The impact of panitumumab treatment on survival and quality of life in patients with RAS wild-type metastatic colorectal cancer

Cancer Management and Research ◽

10.2147/cmar.s186042 ◽

2019 ◽

Vol Volume 11 ◽

pp. 5911-5924 ◽

Cited By ~ 3

Author(s):

Francesca Battaglin ◽

Alberto Puccini ◽

Selma Ahcene Djaballah ◽

Heinz-Josef Lenz

Keyword(s):

Quality Of Life ◽

Colorectal Cancer ◽

Wild Type ◽

PD-031 An exploratory study-level meta-analysis assessing the impact of early tumour shrinkage on overall survival in patients with RAS wild-type metastatic colorectal cancer receiving first-line treatment in three randomised panitumumab trials

Annals of Oncology ◽

10.1093/annonc/mdw200.31 ◽

2016 ◽

Vol 27 ◽

pp. ii114 ◽

Cited By ~ 3

Author(s):

F. Rivera ◽

M. Karthaus ◽

M. Valladares-Ayerbes ◽

J. Gallego ◽

R. Koukakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Overall Survival ◽

Exploratory Study ◽

Meta Analysis ◽

Line Treatment ◽

Wild Type ◽

First Line ◽

Tumour Shrinkage ◽

The Impact ◽

First Line Treatment

Exploration of time points and cut-off values for early tumour shrinkage to predict survival outcomes of patients with metastatic colorectal cancer treated with first-line chemotherapy using a biexponential model for change in tumour size

ESMO Open ◽

10.1136/esmoopen-2017-000275 ◽

2017 ◽

Vol 2 (5) ◽

pp. e000275 ◽

Cited By ~ 7

Author(s):

Kentaro Sakamaki ◽

Yosuke Kito ◽

Kentaro Yamazaki ◽

Naoki Izawa ◽

Takashi Tsuda ◽

...

Keyword(s):

Colorectal Cancer ◽

Tumour Size ◽

Survival Outcomes ◽

First Line ◽

Time Points ◽

Tumour Shrinkage ◽

Biexponential Model ◽

Line Chemotherapy

149PD Association between early tumour shrinkage (ETS) and outcomes in RAS-wild type (WT) patients (pts) with metastatic colorectal cancer (mCRC) receiving first-line FOLFOX or FOLFIRI + cetuximab every other week in the APEC study

Annals of Oncology ◽

10.1093/annonc/mdv523.10 ◽

2015 ◽

Vol 26 ◽

pp. ix42

Author(s):

A.-L. Cheng ◽

G.H. Cornelio ◽

L. Shen ◽

T.J. Prince ◽

T.-S. Yang ◽

...

Keyword(s):

Colorectal Cancer ◽

Wild Type ◽

First Line ◽

Tumour Shrinkage

Impact of depth of response (DpR) on survival in patients (pts) with RAS wild-type (WT) metastatic colorectal cancer (mCRC) receiving first-line panitumumab + FOLFOX4 vs FOLFOX4

Annals of Oncology ◽

10.1093/annonc/mdw370.33 ◽

2016 ◽

Vol 27 ◽

pp. vi160 ◽

Cited By ~ 1

Author(s):

S. Siena ◽

F. Rivera Herrero ◽

J.-Y. Douillard ◽

J. Taieb ◽

R. Koukakis ◽

...

Keyword(s):

Colorectal Cancer ◽

Wild Type ◽

First Line ◽

Depth Of Response